NRx Pharmaceuticals, Inc. cash flow to debt ratio of -2.24K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

NRx Pharmaceuticals, Inc.'s free cash flow has decreased 32.67% from $-10.64M last year to $-14.11M, signaling decreasing performance

NRx Pharmaceuticals, Inc.'s debt to equity ratio is -0.07, signaling that the company spent its equity and risk bankruptcy.

NRx Pharmaceuticals, Inc.'s debt to equity ratio is -0.07, signaling that the company spent its equity and risk bankruptcy.

NRx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

NRx Pharmaceuticals, Inc.'s interest coverage ratio is -19.02, which means that the company struggles to meet interest obligations, signaling financial risk.

NRx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

NRx Pharmaceuticals, Inc.'s short-term liabilities of $28.58M exceed its short-term assets of $8.89M, signaling financial risk

NRx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

NRx Pharmaceuticals, Inc.'s return on equity of 107.73%, is higher than 15.00%, indicating good performance

NRx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

NRx Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

NRx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

NRx Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

NRx Pharmaceuticals, Inc.'s yearly earnings has decreased 13.91% since last year from $-25.13M to $-28.62M, signaling decreasing performance

NRx Pharmaceuticals, Inc.'s yearly revenue has increased % since last year from $0.00 to $1.23M, signaling increasing performance

ROIC 133.44% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

NRx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

NRx Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

NRx Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

NRx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

NRx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NRx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

NRx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

NRx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

NRx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

NRx Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

NRx Pharmaceuticals, Inc. has a price-to-sales ratio of 47.25x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue